Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
—
Status
Completed
Study type
Observational
Enrollment
581actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-10-24 | actual | When the study began enrolling |
| Primary completion | 2025-11-04 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-04 | actual | The whole study's end, after follow-up |
| First posted | 2019-11-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Atopic Dermatitis (AD)
- Asthma
Intervention
- Drug: dupilumab — also filed as REGN668, Dupixent®, SAR23189
Primary outcome
what the primary-completion date above is the date OFRate of major structural defects
measured Up to 1 Year of Age
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed